Ovarian Cancer Coverage from Every Angle

Does Trametinib Treatment Improve Outcomes in Rare Ovarian Cancer Subtype?

By: Kayci Reyer
Posted: Monday, November 4, 2019

According to research presented at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona (Abstract LBA61), the MEK inhibitor trametinib resulted in improved survival outcomes in women with low-grade serous carcinoma of the ovary or peritoneum, a rare ovarian cancer subtype, compared with physician’s standard of care. Weekly paclitaxel, pegylated liposomal doxorubicin, topotecan, letrozole, and tamoxifen were the standard-of-care treatments used in this study.

“Compared to physician’s choice standard of care, trametinib was associated with significantly improved progression-free survival and objective response rate in women with recurrent low-grade serous carcinoma of the ovary or peritoneum,” concluded David M. Gershenson, MD, of the MD Anderson Cancer Center, and colleagues.

The study included 260 patients enrolled between February 2014 and April 2018 who were randomly assigned to receive either 2 mg of trametinib daily or one of five standard-of-care treatment options. Treatment continued until disease progression occurred, with patients who experienced disease progression during standard-of-care treatment allowed to switch to trametinib treatment.

At a median follow-up of 31.4 months, trametinib resulted in markedly improved progression-free survival (median 13.0 vs. 7.2 months), objective response rate (26.2% vs. 6.2%), and response duration (median 13.63 vs. 5.88 months). Median overall survival was 37.0 months with trametinib and 29.2 months with the standard of care.

No significant treatment effects associated with quality of life were reported. The primary adverse events of at least grade 3 in trametinib versus standard of care were hematologic toxicity (13.4% vs. 9.4%), gastrointestinal toxicity (27.6% vs. 29%), skin toxicity (15% vs. 3.9%), and vascular toxicity (18.9% vs. 8.6%). A total of 88 patients switched from standard of care to trametinib following disease progression; this crossover group experienced a median progression-free survival of 10.8 months and an objective response rate of 15%.

Disclosure: The study authors’ disclosure information may be found at cslide.ctimeetingtech.com.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.